Dr. Scott M. Friedman, MD
Claim this profileFlorida Retina Consultants
Studies Macular Edema
Studies Diabetic Macular Edema
2 reported clinical trials
3 drugs studied
Affiliated Hospitals
Clinical Trials Scott M. Friedman, MD is currently running
Fenofibrate
for Diabetic Retinopathy
This randomized trial will evaluate the effect of fenofibrate compared with placebo for prevention of diabetic retinopathy (DR) worsening through 6 years of follow-up in eyes with mild to moderately severe non-proliferative DR (NPDR) and no CI-DME at baseline. In addition to evaluating efficacy, this study aims to evaluate the feasibility of a model for ophthalmologists to prescribe or collaborate with a primary care provider such as an internist/endocrinologist to prescribe and monitor the drug safely. If this study demonstrates that fenofibrate is effective for reducing the onset of proliferative diabetic retinopathy (PDR) or and the results are adopted by the community of retina specialists, a new strategy to prevent vision threatening complications of diabetes could be widely adopted. Widespread use of an oral agent effective at reducing worsening of DR would decrease the numbers of patients who undergo more invasive and much more expensive treatment for DR and who are consequently at risk for side effects that adversely affect visual function. This study will also assess the relationship of glycemic variability, as measured by continuous glucose monitoring with DR outcomes. Ancillary studies will characterize functional and structural outcomes in this cohort.
Recruiting1 award Phase 35 criteria
Tonabersat
for Diabetic Macular Edema
This randomized clinical trial will evaluate the effect of tonabersat compared with placebo on central subfield thickness (CST) in eyes with center-involved diabetic macular edema (CI-DME) and good visual acuity.
Recruiting0 awards Phase 23 criteria
More about Scott M. Friedman, MD
Clinical Trial Related3 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Scott M. Friedman, MD has experience with
- Placebo
- Tonabersat
- Fenofibrate
Breakdown of trials Scott M. Friedman, MD has run
Macular Edema
Diabetic Macular Edema
Retinal Disease
Diabetic Retinopathy
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Scott M. Friedman, MD specialize in?
Scott M. Friedman, MD focuses on Macular Edema and Diabetic Macular Edema. In particular, much of their work with Macular Edema has involved treating patients, or patients who are undergoing treatment.
Is Scott M. Friedman, MD currently recruiting for clinical trials?
Yes, Scott M. Friedman, MD is currently recruiting for 2 clinical trials in Lakeland Florida. If you're interested in participating, you should apply.
Are there any treatments that Scott M. Friedman, MD has studied deeply?
Yes, Scott M. Friedman, MD has studied treatments such as Placebo, Tonabersat, Fenofibrate.
What is the best way to schedule an appointment with Scott M. Friedman, MD?
Apply for one of the trials that Scott M. Friedman, MD is conducting.
What is the office address of Scott M. Friedman, MD?
The office of Scott M. Friedman, MD is located at: Florida Retina Consultants, Lakeland, Florida 33805 United States. This is the address for their practice at the Florida Retina Consultants.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.